Detailed Information on Publication Record
2019
Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset
COORAY, Charith, Michael MAZYA, Robert MIKULÍK, Lubomir JURAK, Miroslav BROZMAN et. al.Basic information
Original name
Safety and Outcome of Intravenous Thrombolysis in Stroke Patients on Prophylactic Doses of Low Molecular Weight Heparins at Stroke Onset
Authors
COORAY, Charith (752 Sweden, guarantor), Michael MAZYA (752 Sweden), Robert MIKULÍK (203 Czech Republic, belonging to the institution), Lubomir JURAK (203 Czech Republic), Miroslav BROZMAN (703 Slovakia), Peter RINGLEB (276 Germany), Anand DIXIT (826 United Kingdom of Great Britain and Northern Ireland), Danilo TONI (380 Italy) and Niaz AHMED (752 Sweden)
Edition
Stroke, Dallas, Lippincott Williams & Wilkins, 2019, 0039-2499
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30103 Neurosciences
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 7.190
RIV identification code
RIV/00216224:14110/19:00112522
Organization unit
Faculty of Medicine
UT WoS
000469350000039
Keywords in English
cerebral hemorrhage; comorbidities; hematoma; heparin; thrombosis
Tags
International impact, Reviewed
Změněno: 8/2/2021 13:40, Mgr. Tereza Miškechová
Abstract
V originále
Background and Purpose-There are limited data on intravenous thrombolysis treatment in patients with ischemic stroke who have received prophylactic doses of low molecular weight heparins (LMWHs). We aimed to evaluate the safety and outcomes of intravenous thrombolysis treatment in stroke patients taking thromboprophylactic doses of LMWH. Methods-We analyzed 109291patients treated with intravenous thrombolysis, recorded in the Safe Implementation of Treatments in Stroke International Thrombolysis Register between 2003 and 2017 not taking oral anticoagulants or therapeutic doses of heparin at stroke onset. One thousand four hundred eleven patients (1.3%) were on prophylactic LMWH for deep venous thrombosis prevention. Outcome measures were symptomatic intracerebral hemorrhage, parenchymal hematoma, death within 7 days and 3 months, and functional dependency at 3 months. Results-Patients on LMWH were older, had more severe strokes, more prestroke disability, and comorbidities than patients without LMWH. There was no significant increase in adjusted odds ratios (aOR) for symptomatic intracerebral hemorrhage (aOR, 1.02 [95% CI, 0.48-2.17] as per Safe Implementation of Treatments in Stroke -MOST, aOR, 0.95 [0.59-1.53] per ECASS II]), nor for 7-day mortality (aOR, 1.14 [0.82-1.59]), in the prophylactic LMWH group. The LMWH group had a higher aOR for 3-month mortality (aOR, 1.94 [1.49-2.53]) and functional dependency, aOR, 1.44 (1.10-1.90). Propensity score analysis matching patients on baseline characteristics removed differences between groups on all outcomes except 3-month mortality. Conclusions-Intravenous thrombolysis in patients with acute ischemic stroke on treatment with prophylactic doses of LMWH at stroke onset is not associated with an increased risk of symptomatic intracerebral hemorrhage or early death.
Links
| LM2015090, research and development project |
|